Doctors say PCSK9 inhibitor use should be limited

Leading physicians said the use of newly FDA-approved proprotein convertase subtilisin kexin type 9 (PCSK9) inhibitors should be limited to a small number of patients who cannot tolerate statins.

The doctors spoke at a "Rethinking Cholesterol" panel presented by Harvard T.H. Chan School of Public Health in collaboration with Reuters.

This summer, the FDA approved alirocumab (Praluent, Regeneron Pharmaceuticals and Sanofi Aventis) and evolocumab (Repatha, Amgen) as an adjunct to diet and exercise to lower low-density lipoprotein cholesterol.